article · Clinical Infectious Diseases

Risk of Major Adverse Cardiovascular Events With Dolutegravir Versus Efavirenz-Based Antiretroviral Therapy: Emulated Target Trials Using Routine, De-Identified Data From South Africa

Jienchi Dorward
Kwabena Asare
Shirley Collie
Johan van der Molen
Kwena Tlhaku
Xolani Masombuka
Claudia Pastellides
Lara Lewis
Christian Bottomley
Jennifer Anne Brown
Dave Jacobs
Nigel Garrett

2026Open accessUniversity of KwaZulu-Natal

In plain language

The abstract on record is too brief for a reliable plain-language summary, so none has been generated.

Abstract

Among PLHIV in South Africa we found no increased MACE with TLD.

Research topics

HIV-related health complications and treatments
HIV/AIDS drug development and treatment
HIV/AIDS Research and Interventions

Sustainable Development Goals

Good Health and Well-being

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

View on publisher site Record on OpenAlex

DOI: 10.1093/cid/ciag155

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.

New to MARATTO™? Create a free account.